Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Aroplatin · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Aroplatin | DRUG | - |
Inclusion Criteria: 1. Advanced solid malignancies or B-cell lymphoma 2. Less than or equal to 5 anti-cancer treatment regimens, which must be concluded at least four weeks prior to the first planned L-NDDP administration 3. Measurable disease 4. Eastern Cooperative Oncology Group (ECOG) performanc...
Aroplatin is an investigational small molecule being studied for the treatment of advanced solid malignancies or B-cell lymphoma. It is a liposomal formulation of the platinum compound L-NDDP. As of the available data, it has been evaluated in a Phase 1 clinical trial for these conditions.
Aroplatin is a platinum-based small molecule. Platinum compounds work by forming DNA crosslinks, which can inhibit tumor cell division and lead to cell death. However, the specific molecular target of Aroplatin has not been detailed in the available information.
Aroplatin is being developed by Agenus Inc., a biopharmaceutical company. Agenus is publicly traded under the ticker symbol AGEN. The company is conducting clinical research on this investigational oncology drug.
Aroplatin is in Phase 1 of clinical development. It has completed a Phase 1 trial, and there are no active trials currently listed. The drug remains investigational and has not been approved by regulatory authorities.
Aroplatin has been studied in one completed clinical trial, identified as NCT00316511. This Phase 1 study enrolled 21 participants with advanced solid malignancies or B-cell lymphoma. The trial was conducted in the United States and included adults aged 18 years and older.
Yes, Aroplatin is also known as L-NDDP. The clinical trial NCT00316511 is titled 'Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma,' confirming that L-NDDP is the chemical name for Aroplatin.